About Us

Drugging the Undruggable to Treat High Mortality Cancers

Sapience Therapeutics is focused on discovering and developing peptide-based therapeutics to previously "undruggable" targets for major unmet medical needs, particularly high mortality cancers.

Our drug candidates target protein-protein interactions (PPIs) that are responsible for either making the cells cancerous or dampening the immune response against tumors. These targets are considered undruggable because they are PPIs that reside inside of the cell, making them difficult to treat with small molecule drugs such as chemotherapies (which are incapable of disrupting PPIs) or biologic-based drugs such as monoclonal antibodies (which are too big to enter the cell). We aim to combine the best features of these two drug classes by developing cell-penetrating peptides that can enter cells and disrupt these PPIs.

Learn More

Science Backed by Strong Leadership

Our world-class team of executives and scientists are helping us pave the way to providing therapeutics for significant unmet medical needs.